ScotiaBank Lifts AbbVie Price Target to $320 as Stock Trades Near 52-Week Highs
By TrendSpider Editor
ABBV market update based on latest analyst_update data.
ScotiaBank Lifts AbbVie Price Target to $320 as Stock Trades Near 52-Week Highs
ScotiaBank analyst Louise Chen has reaffirmed a "buy" rating on AbbVie Inc. while raising the price target from $280 to $320, implying meaningful upside from the stock's current price of $271.41. The confirmation comes as ABBV trades not only near its 52-week high of $269.39 but has actually broken above it, reflecting strong recent momentum. With a 52-week low of $191.00, the stock has staged an impressive run and now sits at a level that tests whether bulls can sustain the breakout.Key Drivers of the ABBV Stock Move
- Main Catalyst: ScotiaBank analyst Louise Chen confirmed a "buy" rating on AbbVie while raising the price target by $40, from $280 to $320. The revised target now stands as the consensus average price target, signaling a constructive view on ABBV's fundamental trajectory heading into the remainder of 2026.
- Bull Case: The new $320 price target represents approximately 17.9% upside from the current price of $271.41. The fact that Chen is raising the target at a point when ABBV is already trading above its prior 52-week high of $269.39 suggests conviction that the recent breakout has fundamental support, not just technical momentum.
- Bear Case: With ABBV now trading above its 52-week high and having gained 1.73% in today's session alone, some investors may view the stock as extended in the near term. A price target raise at peak levels can sometimes reflect analysts catching up to price action rather than leading it, raising questions about whether the easy gains are already priced in.
ABBV Analyst Ratings and Price Targets
ScotiaBank analyst Louise Chen confirmed a "buy" rating on AbbVie while raising the price target to $320 from a prior target of $280. This is the sole analyst action recorded in today's session, with zero upgrades and zero downgrades. The consensus average price target currently stands at $320, matching ScotiaBank's revised figure exactly.ABBV Seasonality
October has historically been a transitional month for large-cap pharmaceutical names, with investor attention shifting toward year-end positioning and pipeline catalysts heading into major medical conferences in the fourth quarter. A price target reaffirmation in early October may reflect analyst preparation for anticipated news flow in the weeks ahead.ABBV Relative Performance
ABBV's 1.73% gain on Thursday puts it in a strong position relative to the broader pharmaceutical and healthcare sector, particularly notable given that the stock is simultaneously breaking above its prior 52-week high of $269.39. Trading at $271.41, AbbVie is outpacing many of its large-cap pharmaceutical peers that continue to trade within established ranges rather than setting new highs, underscoring the relative strength that likely contributed to ScotiaBank's decision to raise its price target today.More on ABBV
- AbbVie Sees Bullish $1.5M Call Bet as Stock Breaks Above 52-Week High
- ScotiaBank Lifts AbbVie Price Target to $320 as Stock Trades Near 52-Week High
- AbbVie Stock Climbs 1.24% to $266.15, Pressing Against Its 52-Week High
- AbbVie Stock Hovers Just Below Its 52-Week High of $269.39 as Momentum Holds
- AbbVie Stock Hovers Near 52-Week High of $269.39 as Shares Slip 0.24%
Latest Market News
- UnitedHealth Group Sees $4.1 Million Bearish Put Sweep as Stock Hovers Near Session Lows
- RBC Capital Slashes PEP Price Target to $150 as Pepsi Trades Near 52-Week Low
- Citigroup and Mizuho Reaffirm AMD Buy Ratings With Sharply Higher Price Targets
- ARM Holdings Sees $4.2M in Bearish Options Flow as Stock Slides 2.75%
- Walmart Sees $1.18 Million Bullish Call Sweep as Stock Trades Near 52-Week Lows
- AbbVie Sees Bullish $1.5M Call Bet as Stock Breaks Above 52-Week High